By Erin Harris, Editor-In-Chief, Cell & Gene
Follow Me On Twitter @ErinHarris_1
My colleague, Chief Editor of Bioprocess Online’s Matt Pillar, hosts The Business of Biotech podcast, and I’m guest hosting a five-part miniseries focused on cell and gene therapy. Throughout the miniseries, you’ll hear from executives from Acepodia, Orchard Therapeutics, Celyad Oncology, and Sio Gene Therapies. You’ll hear about manufacturing wins and fumbles, unmet medical need, the participant’s path to the C-suite, and more.
Our first episode features Selecta Biosciences, Inc. President & CEO Dr. Carsten Brunn, and he answers our questions about the company’s ImmTOR platform. During the pod, Dr. Brunn talks about immunogenicity of adeno-associated virus (AAV) vectors challenge that gene therapy companies face and how Selecta is addressing the challenge. He talks about the companies Selecta partners with and why, next big steps, and more.
Visit Cell & Gene or wherever you get your podcasts to download and listen to each episode, which drop on Mondays.